clinical trial | Q30612 |
P3098 | ClinicalTrials.gov ID | NCT01270438 |
P6099 | clinical trial phase | phase II clinical trial | Q42824440 |
P582 | end time | 2011-08-01 | |
P1050 | medical condition | adenocarcinoma | Q356033 |
P2899 | minimum age | 18 | |
P1132 | number of participants | 0 | |
P4844 | research intervention | calcium oxalate | Q412399 |
bevacizumab | Q413299 | ||
leucovorin calcium | Q27077063 | ||
fluorouracil | Q238512 | ||
P6153 | research site | Mayo Clinic | Q1130172 |
Memorial Sloan Kettering Cancer Center | Q1808012 | ||
P580 | start time | 2010-12-01 | |
P8363 | study type | interventional study | Q78089383 |
P1476 | title | A Phase 2 Study of RO4929097 (NSC 749225) in Combination With FOLFOX Plus Bevacizumab Versus FOLFOX Plus Bevacizumab Alone for the First-Line Treatment of Patients With Metastatic Colorectal Cancer (NCI #8467) |
Search more.